Loading live market data…

BridgeBio Pharma, Inc.

NASDAQ:BBIO

$84.09 USD

$1.01 (1.22%)

Volume
2.74M
Average Volume
3.63M
Market Capitalization
$16.47B
P/E Ratio
-22.42
Dividend Yield
0.00%
Price Target
$100.00
Year High
$93.42
Year Low
$42.09
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.44

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Neil Kumar
Industry Biotechnology
Sector Healthcare
Current Symbol BBIO
CUSIP 10806X102
CIK 0001743881
Web https://www.bridgebio.com
Phone 650 391 9740
Currency USD
Employees 839
Country US

Liquidity

Debt-to-Equity Ratio -1.49
Payout Ratio 0.00
Current Ratio 1.44
Quick Ratio 1.40
Cash Ratio 1.08

Sales & Book Value

Annual Sales $502.08M
Price / Sales 28.40
Cash Flow -2.33
Price / Cash Flow -36.27
Price / Book -7.22

Price Target and Rating

Average Stock Price Forecast $100.00
High Stock Price Forecast $157.00
Low Stock Price Forecast $83.00
Forecast Upside/Downside -15.91%
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 26 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-3.79
Trailing P/E Ratio -22.42
PEG Ratio 2.45
P/E Growth 2.45
Net Income $-729.31M
Net Margin -125.17%
Pretax Margin -126.20%
Return on Equity 36.00%
Return on Assets -52.95%

Financials Score

AltmanZ Score -2.13
Piotroski Score 2.00
Working Capital 362.02M
Total Assets 1.37B
Ebit -617.74M
Market Cap 16.27B
Total Liabilities 3.64B

Poll Results

About BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phas ... e 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

2026-07-13 12:25:30

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

2026-07-12 09:55:00

BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-07-10 16:01:00

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 37 new employees in restricted stock units for an aggregate of 83,283 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High

2026-07-10 13:25:26

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.

BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?

2026-07-10 06:36:04

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth

2026-07-08 13:31:08

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.

BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts

2026-07-08 13:25:34

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.

Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead

2026-07-08 13:25:32

BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.

Frequently Asked Questions

What is the current BridgeBio Pharma, Inc. (BBIO) stock price?

BridgeBio Pharma, Inc.(NASDAQ:BBIO) stock price is $84.09 in the last trading session. During the trading session, BBIO stock reached the peak price of $93.415 while $42.09 was the lowest point it dropped to. The percentage change in BBIO stock occurred in the recent session was 1.22% while the dollar amount for the price change in BBIO stock was $1.01.

BBIO's industry and sector of operation?

The NASDAQ listed BBIO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BBIO?

Charles J. Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director
Neil Kumar | Co-Founder, Chief Executive Officer & Director
Richard H. Scheller | Chairman of Research & Development
Matthew Outten | Chief Commercial Officer
Maricel Apuli | Chief Accounting Officer

How many employees does BBIO have?

Number of BBIO employees currently stands at 839. BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, US.

Link for BBIO official website?

Official Website of BBIO is: https://www.bridgebio.com

How do I contact BBIO?

BBIO could be contacted at phone #650 391 9740 and can also be accessed through its website. BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, US.

How many shares of BBIO are traded daily?

The average number of BBIO shares traded daily for last 3 months was 3.63M.

What is the market cap of BBIO currently?

The market value of BBIO currently stands at $16.47B with its latest stock price at $84.09